NCIt definition : A cancer vaccine consisting of a truncated recombinant HER2/neu peptide (dHER2) combined
with the immunoadjuvant AS15 with potential immunostimulatory and antineoplastic activities.
Upon administration, dHER2 AS15 vaccine may stimulate the host immune response to
mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress
the HER2/neu protein, resulting in tumor cell lysis. The tumor-associated antigen
(TAA) HER2/neu is often overexpressed by a variety of tumor cell types; dHER2 includes
amino acids 1-645 or 1-653 of the extracellular domain (ECD) and an immunogenic carboxyl
terminal autophosphorylation portion of the intracellular domain (ICD). AS15 is an
adjuvant formulation that contains the adjuvant systems AS01B and AS07A; AS01 B is
composed of liposomes containing 3D-MPL and QS21 and AS07A is composed of the synthetic
oligodeoxynucleotide (ODN) Toll-like receptor-9 (TLR9) agonist CpG 7909.;
Semantic type(s)